Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

11,124 total articles

Nebius: Betting on a Pullback After a 684% Revenue Run

Nebius: Betting on a Pullback After a 684% Revenue Run

Nebius reported a 684% revenue surge that has captivated traders. That growth looks real on the top line, but a thin liquidity profile, likely one-time drivers and opaque cash flow dynamics create a measurable downside if earnings quality or cash visibility disappoint. This is a tactical short idea with clearly defined entry, stop and targets over …

Buy the Dip, Brace for the Pain: MercadoLibre for Patient Bulls

Buy the Dip, Brace for the Pain: MercadoLibre for Patient Bulls

MercadoLibre (MELI) is under pressure as management sacrifices margins to defend Latin American market share and scale fintech products. Current weakness creates a tradeable long opportunity: enter near $1690, stop at $1525, target $2400 over a long-term window (180 trading days). Expect volatility in the next 10-45 trading days as investments read…

Microsoft: Expensive vs. History, But Setup for a Mid-Term Upside

Microsoft: Expensive vs. History, But Setup for a Mid-Term Upside

Microsoft ($MSFT) trades well above its 50-day average and at a premium to the market, but fundamentals remain solid: $3.16T market cap, $72.9B free cash flow, 30% ROE, and low leverage. For traders willing to accept limited valuation risk, a controlled long with a $426 entry, $400 stop and $455 target over a mid-term (45 trading days) horizon bala…

Dave Is Positioned to Lead the Next Wave of Fintech Winners

Dave Is Positioned to Lead the Next Wave of Fintech Winners

Dave Inc. looks like a fintech that has graduated from early-stage promise to near-term commercial clarity. With 2025 revenue up roughly 60%, net income of $195.9M, strong free cash flow of $326.5M, and a market cap near $3.4B, Dave is delivering both growth and profitability. This trade plan targets $420 over a 180-trading-day window while protect…

Kohl's Stabilization Looks Real — Tactical Long After Earnings Beat

Kohl's Stabilization Looks Real — Tactical Long After Earnings Beat

Kohl's ($KSS) delivered an earnings beat while management signaled no new store closures and a focus on omnichannel execution. The stock has recovered from its spring lows and now trades on single-digit earnings multiples with a 3.9% yield and positive technical momentum. We upgrade to a tactical long for a mid-term swing (45 trading days) with a c…

Buy Netflix Now: This Is the Bottom the Market Can’t Ignore

Buy Netflix Now: This Is the Bottom the Market Can’t Ignore

Netflix is sitting above a clean technical and fundamental floor after a painful selloff. The business is cash-generative, has strong returns on capital, and recent one-time items that distorted reported EPS are fading. With a market cap near $361B, EV/EBITDA of 9.5 and free cash flow of roughly $11.9B, the risk-reward favors a tactical long: entry…

AMD Upgrade: Play the AI Upside Without Betting on Beating Nvidia

AMD Upgrade: Play the AI Upside Without Betting on Beating Nvidia

AMD is positioned to capture meaningful AI-related revenue growth through EPYC CPUs, GPU accelerators and differentiated system-level wins. We upgrade AMD to a buy and present a concrete trade plan calibrated to a 180-trading-day horizon that assumes continued data-center demand and margin improvement without needing AMD to displace Nvidia outright…

HP Inc. - Market Is Pricing Cyclical Fear, Not Cash Flow Reality

HP Inc. - Market Is Pricing Cyclical Fear, Not Cash Flow Reality

HP reported a solid Q2 with revenue of $14.41B and EPS of $0.86, yet shares trade at just ~9.4x earnings and yield ~4.6%. Rising memory costs justify caution, but the company is a free-cash-flow generator ($2.88B last twelve months) with an enterprise value of ~$29.9B. This trade idea argues the risk/reward favors a mid-term long while treating the…

Buy Q32 Bio Ahead of Bempikibart Push and Mid-2026 Data Window

Buy Q32 Bio Ahead of Bempikibart Push and Mid-2026 Data Window

Q32 Bio (QTTB) is a clinical-stage biotech focused on immune rebalancing through IL-7/TSLP receptor and complement programs. With a market cap near $200M, a lean balance sheet, and an upcoming mid-2026 data cadence tied to bempikibart advancement, we rate QTTB Buy. Our trade plan: enter at $11.81, stop $9.00, target $22.00 over a long-term horizon …

Novo Nordisk: Cheap Enough to Back a GLP-1 Comeback Bet

Novo Nordisk: Cheap Enough to Back a GLP-1 Comeback Bet

Novo Nordisk (NVO) is pricing in persistent GLP-1 share loss and a protracted growth slowdown. Recent regulatory wins (CHMP recommendation for Wegovy 7.2 mg single-dose pen and an oral semaglutide approval recommendation) and still-healthy fundamentals argue for a tactical long. The trade targets a recovery toward $65 over the next 180 trading days…

Japan Tobacco: Buy the Calm — a Mid-Range Swing Play Around $19

Japan Tobacco: Buy the Calm — a Mid-Range Swing Play Around $19

Japan Tobacco (JAPAY) is a beaten-but-not-broken global tobacco incumbent trading on the OTC market. The stock sits near its 20/50-day moving averages, offers a 2.84% yield and a mid-teens P/E, making it an attractive, lower-volatility swing trade. Entry at $19.00, stop at $18.00 and a target of $20.60 balances risk with a clear technical upside.

AMD's Next AI Wave: Position for Platform Expansion, Not Just GPUs

AMD's Next AI Wave: Position for Platform Expansion, Not Just GPUs

Advanced Micro Devices is moving from a GPU-centric rally to a broader AI platform play that includes CPUs, accelerators, networking and custom silicon. The stock is richly valued - market cap ~$808B and a P/E north of 160 - but fundamentals and visible catalysts (Q1 strength, a $10B Taiwan commitment, rising AI capex) support further upside. This …